Skip to main content
Research
  1. Queen Mary University of London
  2. Research
  3. Publications

Publications: DR Upkar Gill

Back to Search
( 2024 ) . HBV Biomarkers and Their Role in Guiding Treatment Decisions . Seminars in Liver Disease vol. 44 , ( 04 ) 474 - 491 .
( 2024 ) . A Genes & Health pilot recall study of intrahepatic cholestasis of pregnancy and cholestatic liver disease .
( 2024 ) . Auto-antibodies against interferons are common in people living with chronic hepatitis B virus infection and associate with PegIFN non-response .
( 2024 ) . Characterisation of HBV and co-infection with HDV and HIV through spatial transcriptomics . eGastroenterology vol. 2 , ( 3 ) e100067 - e100067 .
( 2024 ) . HIV/HBV coinfection remodels the immune landscape and natural killer cell ADCC functional responses . Hepatology vol. 80 , ( 3 ) 649 - 663 .
( 2020 ) . CD4 T cells in hepatitis B virus: “You don’t have to be cytotoxic to work here and help” . Journal of Hepatology vol. 72 , ( 1 ) 9 - 11 .
( 2019 ) . HCMV jogs the ‘memory’ of NK cells in HBV . Journal of Hepatology vol. 70 , ( 3 ) 343 - 345 .
( 2016 ) . Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8 T Cells in the Same Host . Cell Reports vol. 16 , ( 5 ) 1243 - 1252 .
( 2016 ) . CXCR6 marks a novel subset of T-betloEomeshi natural killer cells residing in human liver . Scientific Reports vol. 6 , ( 1 ) Article 26157 ,
( 2015 ) . PTU-103 Characterisation of the immune profile in chronic hepatitis b patients following nucleos(t)ide discontinuation by cytof mass cytometry . Gut . vol. 64 , A106.2 - A107 .
( 2015 ) . PTU-106 Identifying true immune-tolerant disease in children and young adults with chb using quantified hepatitis b surface antigen levels . Gut . vol. 64 , A108.1 - A108 .
( 2015 ) . PTU-107 Defining the low-risk inactive carrier in chronic hepatitis b with qhbsag: do the same rules apply in children and young adults? . Gut . vol. 64 , A108.2 - A109 .
( 2015 ) . PTU-116 Functional immune restoration correlates with HBSAG decline and may predict treatment response on sequential NUC therapy in CHB . Gut . vol. 64 , A113.1 - A113 .
( 2015 ) . PTU-117 Sequential NUC therapy following pegylated interferon provides a greater decline in HBSAG and potentially offers a treatment advantage over current therapies . Gut . vol. 64 , A113.2 - A114 .
( 2015 ) . Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells . Nature Medicine vol. 21 , ( 6 ) 591 - 600 .
( 2015 ) . P0474 : Characterisation of the immune profiles of chronic hepatitis B patients following NUC discontinuation by cyTOF mass cytometry . Journal of Hepatology . vol. 62 , S491 - S491 .
( 2015 ) . P0478 : NKG2D-dependent cross-talk between NK cells and CD4 T cells in chronic hepatitis B . Journal of Hepatology . vol. 62 , S493 - S493 .
( 2015 ) . P0485 : Functional immune restoration correlates with HBsAg decline and may predict treatment response on sequential NUC therapy in chronic hepatitis B . Journal of Hepatology . vol. 62 , S496 - S496 .
( 2014 ) . Assessment of Bone Mineral Density in Tenofovir-Treated Patients With Chronic Hepatitis B: Can the Fracture Risk Assessment Tool Identify Those at Greatest Risk? . Journal of Infectious Diseases vol. 211 , ( 3 ) 374 - 382 .
( 2014 ) . Toll-Like Receptor 8 Agonist and Bacteria Trigger Potent Activation of Innate Immune Cells in Human Liver . PLoS Pathogens vol. 10 , ( 6 ) e1004210 - e1004210 .
( 2014 ) . O106 CLONAL HEPATOCYTE REPOPULATION IN THE YOUNG ADULT HBV INFECTED LIVER CHALLENGES THE CONCEPT OF A GENERIC IMMUNE TOLERANT DISEASE PHASE . Journal of Hepatology . vol. 60 , S43 - S43 .
( 2014 ) . P132 MYELOID-DERIVED SUPPRESSOR CELLS MEDIATE IMMUNOTOLERANCE IN CHRONIC HEPATITIS B (CHB) THROUGH ARGININE DEPRIVATION . Journal of Hepatology . vol. 60 , S109 - S109 .
( 2014 ) . P137 THE EXPRESSION OF NKG2D-LIGANDS BY ACTIVATED CD4 T CELLS RENDERS THEM SUSCEPTIBLE TO NK CELL REGULATION IN CHRONIC HEPATITIS B (CHB) . Journal of Hepatology . vol. 60 , S111 - S111 .
( 2014 ) . P152 SEQUENTIAL NUC THERAPY FOLLOWING PEGYLATED INTERFERON-ALPHA EXPOSURE RESTORES INNATE IMMUNE RESPONSES CONFERRING A TREATMENT ADVANTAGE OVER NUC MONOTHERAPY IN CHRONIC HEPATITIS B . Journal of Hepatology . vol. 60 , S116 - S116 .
( 2014 ) . P159 CO-INHIBITORY RECEPTOR LAG-3 POSITIVE CD8 T CELLS PRODUCE IMMUNOSUPPRESSIVE TGF-β IN CHRONIC HBV . Journal of Hepatology . vol. 60 , S118 - S119 .
( 2014 ) . P306 MONOCYTE OXIDATIVE BURST DEFECT PREDICTS RISK OF INFECTION IN ALCOHOLIC HEPATITIS . Journal of Hepatology . vol. 60 , S168 - S168 .
( 2014 ) . Arginase-dependent metabolic regulation of hepatic immunopathology by myeloid-derived suppressor cells . IMMUNOLOGY vol. 143 , 154 - 154 .
( 2014 ) . Functional innate immune responses are restored with sequential NUC therapy following Pegylated Interferon-Alpha exposure and not with NUC monotherapy in Chronic Hepatitis B . HEPATOLOGY . vol. 60 , 1020A - 1021A .
( 2014 ) . High levels of Hepatitis B surface antigen (HBsAg) can exclude significant fibrosis and distinguishes true 'immune-tolerance' in children and young adults with Chronic Hepatitis B . HEPATOLOGY . vol. 60 , 985A - 986A .
( 2013 ) . PWE-143 Sequential Oral Anti-Viral Therapy Following Pegylated-Interferon-Alpha Failure Significantly Increases Hbsag Decline . Gut . vol. 62 , A189.2 - A190 .
( 2013 ) . PWE-144 Frax Score in the Assessment of Bone Mineral Density Changes in Tenofovir Treated Chronic Hepatitis B Patients . Gut . vol. 62 , A190.1 - A190 .
( 2013 ) . 325 PROBING HEPATIC ANTIGEN PRESENTATION IN PATIENTS WITH CHRONIC HBV INFECTION . Journal of Hepatology . vol. 58 , S136 - S136 .
( 2013 ) . 746 INDUCTION MAINTENANCE THERAPY IN CHRONIC HEPATITIS B; STEP-DOWN FROM COMBINATION LAMIVUDINE AND TENOFOVIR TO LAMIVUDINE MONOTHERAPY – A POTENTIAL NEW TREATMENT STRATEGY . Journal of Hepatology . vol. 58 , S302 - S302 .
( 2013 ) . The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells . PLoS Pathogens vol. 9 , ( 3 ) e1003208 - e1003208 .
( 2013 ) . Co-inhibitory receptor LAG-3 positive CD8 T cells produce immunosuppressive TGF-β in chronic HBV . IMMUNOLOGY . vol. 140 , 145 - 145 .
( 2013 ) . Expansion of arginase-expressing myeloid-derived suppressor cells in hepatotropic viral infections . IMMUNOLOGY . vol. 140 , 97 - 97 .
( 2012 ) . Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell–mediated deletion . Journal of Experimental Medicine vol. 210 , ( 1 ) 99 - 114 .
( 2012 ) . IL-10–Producing Regulatory B Cells in the Pathogenesis of Chronic Hepatitis B Virus Infection . The Journal of Immunology vol. 189 , ( 8 ) 3925 - 3935 .
( 2012 ) . Preserved T-Cell Function in Children and Young Adults With Immune-Tolerant Chronic Hepatitis B . Gastroenterology vol. 143 , ( 3 ) 637 - 645 .
( 2012 ) . PMO-148 Evaluation of liver fibrosis in young adult patients with chronic hepatitis B virus . Gut vol. 61 , ( Suppl 2 ) A133.2 - A133 .
( 2012 ) . PMO-175 Can a 3-month “stopping rule” for pegylated-interferon-α be applied to a UK population of chronic hepatitis B infected patients of mixed genotype? . Gut vol. 61 , ( Suppl 2 ) A145.1 - A145 .
( 2012 ) . PMO-176 Induction maintenance treatment in chronic hepatitis B; step-down from tenofovir and lamivudine to lamivudine monotherapy is effective . Gut vol. 61 , ( Suppl 2 ) A145.2 - A145 .
( 2012 ) . PMO-177 Maximal boosting of innate immunity during pegylated interferon-α therapy is reached at 48 weeks in e-antigen positive chronic hepatitis B . Gut vol. 61 , ( Suppl 2 ) A145.3 - A146 .
( 2012 ) . 441 MAXIMAL BOOSTING OF INNATE IMMUNITY DURING PEGYLATED INTERFERON-APLHA THERAPY IS REACHED AT 48 WEEKS IN E-ANTIGEN POSITIVE CHRONIC HEPATITIS B . Journal of Hepatology . vol. 56 , S175 - S175 .
( 2012 ) . Benchmarking disease activity and progression in Chronic Hepatitis B infected young adults . HEPATOLOGY . vol. 56 , 362A - 362A .
( 2012 ) . FRAX score in the assessment of Bone Mineral Density changes in Tenofovir treated Chronic Hepatitis B patients: comparison with bone biochemistry and DEXA scanning . HEPATOLOGY . vol. 56 , 201A - 201A .
( 2011 ) . P61 Bone mineral density loss in tenofovir treated Chronic Hepatitis B Virus (HBV) patients is a consequence of Vitamin D deficiency and not Tenofovir therapy . Gut vol. 60 , ( Suppl 2 ) A28 - A28 .
( 2011 ) . P62 Immunological analysis and clinical profile of Chronic Hepatitis B Virus (HBV) infection in the younger patient . Gut vol. 60 , ( Suppl 2 ) A29 - A29 .
( 2011 ) . Chronic HBV infection: assessment and management of disease in a young adult clinic . Gut . vol. 60 , A230 - A231 .
( 2011 ) . Efficacy of combination tenofovir plus lamivudine versus tenofovir monotherapy in patients with chronic hepatitis B virus . Gut . vol. 60 , A231 - A231 .
( 2011 ) . Factors determining bone mineral density loss in chronic hepatitis B patients: is tenofovir disoproxil fumarate the main culprit? . Gut . vol. 60 , A230 - A230 .
( 2011 ) . Pegylated interferon   modulates innate immunity in eAg positive chronic hepatitis B and determines changes in HBsAg quantification . Gut . vol. 60 , A232 - A232 .
( 2011 ) . Utility of HBsAg quantification in developing an individualised approach to the management of chronic hepatitis B virus in clinical practice . Gut . vol. 60 , A231 - A232 .
( 2011 ) . 70 PEGYLATED INTERFERON ALPHA MODULATES INNATE IMMUNITY IN EAG POSITIVE CHRONIC HEPATITIS B AND DETERMINES CHANGES IN HBSAG QUANTIFICATION . Journal of Hepatology . vol. 54 , S32 - S32 .
( 2011 ) . 713 FACTORS DETERMINING BONE MINERAL DENSITY LOSS IN CHRONIC HEPATITIS B PATIENTS: IS TENOFOVIR DISOPROXIL FUMARATE THE MAIN CULPRIT? . Journal of Hepatology . vol. 54 , S286 - S286 .
( 2011 ) . BONE MINERAL DENSITY LOSS IN TENOFOVIR TREATED CHRONIC HEPATITIS B VIRUS (HBV) PATIENTS IS A CONSEQUENCE OF VITAMIN D DEFICIENCY AND NOT TENOFOVIR THERAPY . HEPATOLOGY . vol. 54 , 1012A - 1012A .
( 2011 ) . IMMUNOLOGICAL ANALYSIS AND CLINICAL PROFILE OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION IN THE YOUNGER PATIENT . HEPATOLOGY . vol. 54 , 1092A - 1093A .
( 2011 ) . Susceptibility of T cells to death ligand-mediated deletion in the liver of chronic hepatitis B virus (CHB) infected patients . IMMUNOLOGY . vol. 135 , 60 - 60 .
Back to Search